Group 1 - The company proposes to increase its authorized share capital from HKD 50 million (5 billion shares) to HKD 400 million (40 billion shares) by issuing an additional 3.5 billion shares with a par value of HKD 0.1 each [1] - The increase in authorized share capital will take effect upon approval by shareholders at a special general meeting [1] Group 2 - The board suggests a rights issue where shareholders will receive 4 new shares for every existing share held, at a subscription price of HKD 0.105 per share, representing a discount of approximately 42.86% [2] - The rights issue aims to raise up to approximately HKD 121.6 million, with estimated net proceeds not exceeding HKD 62.5 million after expenses [2] - The proceeds will be allocated as follows: approximately HKD 41.2 million for repaying overdue bank loans and interest, HKD 13.1 million for repaying shareholder loan balances, HKD 7.7 million for settling trade and other payables, and the remaining HKD 0.5 million for general operational expenses [2]

Core Viewpoint - The company, CNOOC Services (03303.HK), announced a proposed rights issue to raise up to approximately HKD 56.9 million, contingent upon the fulfillment of certain conditions [1] Group 1: Rights Issue Details - The company plans to issue 355,547,898 rights shares at a subscription price of HKD 0.16 per share [1] - The basis for allocation is set at one rights share for every six existing shares held by eligible shareholders on the record date [1] - The rights issue is non-underwritten and participation is limited to eligible shareholders only, excluding ineligible shareholders from participation [1] Group 2: Financial Projections - Assuming no changes in the total issued share capital of the company as of the record date, the maximum net proceeds from the rights issue, after estimated expenses, are expected to be approximately HKD 55.1 million [1]

Core Viewpoint - The company announced the results of its rights issue, indicating a significant acceptance rate and the subsequent arrangements for the unallocated shares [1] Group 1: Rights Issue Results - The company received a total of 5 valid applications for the rights issue, amounting to 167 million shares, which represents approximately 56.39% of the total shares offered under the rights issue [1] - As a result of the valid acceptances, the total number of unallocated shares is 129 million [1] - The company has established a compensation arrangement through a placement agreement with a placement agent to facilitate the subscription of the unallocated shares [1] Group 2: Conditions and Issuance - All conditions related to the rights issue and placement have been fulfilled, making the rights issue and placement unconditional as of January 7, 2026 [1] - The total number of shares to be allotted and issued will be 297 million, which accounts for 100% of the shares offered for subscription under the rights issue [1]

Group 1 - The company, Guangjun Group Holdings (08516), announced that there are no excluded shareholders as of the record date, resulting in no unqualified shareholders failing to sell their rights issue shares [1] - As of the deadline on January 2, 2026, the company received a total of 8 valid applications for a total of 19.6352 million rights issue shares, which represents approximately 47.8% of the total shares offered under the rights issue [1] - The remaining 21.4708 million shares, which were not subscribed, account for about 52.2% of the total shares offered under the rights issue and will be disposed of according to the compensation arrangement [1] Group 2 - The company has made arrangements to sell the 21.4708 million unsubscribed rights issue shares to independent underwriters, as per GEM Listing Rule 10.31(1)(b), to benefit shareholders who participated in the rights issue [1] - A placement agreement was established with the placement agent on May 23, 2025, regarding the placement of the unsubscribed shares during the placement period, with any premium generated above the subscription price to be proportionately paid to non-action shareholders [1] - The placement agent will endeavor to facilitate the subscription of all (or as many as possible) unsubscribed rights issue shares between January 9, 2026, and no later than January 12, 2026 [1]

Core Viewpoint - The article discusses the recent stock transfer of Ying Sheng Science (00209) and its proposed rights issue to raise capital [1] Group 1: Stock Transfer - On January 7, shareholders of Ying Sheng Science transferred shares from lmagi Brokerage Limited to Futu Securities International Hong Kong, with a transfer value of HKD 1.9689 million, representing 5.96% of the company [1] Group 2: Rights Issue - Ying Sheng Science announced a proposal for a rights issue, offering 7 new shares for every existing share held at a subscription price of HKD 0.14 per share [1] - The company aims to issue up to approximately 1.3 billion rights shares, assuming no changes in the number of shares issued as of the record date, to raise a total of approximately HKD 182 million [1]

Core Viewpoint - Hong Kong Communications International Holdings (00248) proposes a rights issue to raise up to approximately HKD 21.8 million by offering 77.83 million shares at a subscription price of HKD 0.28 per share, which represents a discount of about 25.5% from the adjusted closing price of HKD 0.376 per share [1][2]. Group 1: Rights Issue Details - The rights issue is based on a ratio of 1 share for every 2 existing shares held, and the shares to be issued will represent approximately 50.0% of the total issued shares post-consolidation and about 33.3% of the enlarged issued shares [1]. - The maximum gross proceeds from the rights issue, after offsetting approximately HKD 11.5 million owed to a shareholder, is expected to be around HKD 10.3 million, with a net amount of approximately HKD 9.4 million after expenses [2]. - The net proceeds will primarily be used to repay bank loans (approximately HKD 8.5 million or 90% of the net proceeds) and the remaining HKD 0.9 million (10% of the net proceeds) will be allocated for general working capital [2]. Group 2: Share Consolidation Proposal - The board proposes to increase the authorized share capital from HKD 20 million (20 billion existing shares) to HKD 40 million (40 billion shares) pending shareholder approval [3]. - A share consolidation is also proposed, where every 8 existing shares will be consolidated into 1 share, changing the nominal value from HKD 0.01 to HKD 0.08 per consolidated share, effective after shareholder approval [3]. - Following the consolidation, the trading unit on the Stock Exchange will change from 4,000 existing shares to 10,000 consolidated shares [3]. Group 3: Share Value Implications - Based on the current closing price of HKD 0.047 per existing share, the value of a trading unit of 4,000 existing shares is HKD 188, while the estimated value of a trading unit of 10,000 consolidated shares would be HKD 3,760 post-consolidation [4].

Core Viewpoint - Hong Kong Communications International Holdings (00248.HK) plans to increase its authorized share capital and consolidate shares, aiming to raise funds through a rights issue to strengthen its financial position [1][2] Group 1: Share Capital Increase - The board proposes to increase the authorized share capital from HKD 20 million (2 billion existing shares) to HKD 40 million (4 billion existing shares) [1] - This increase will take effect upon approval by shareholders at a special general meeting [1] Group 2: Share Consolidation - A share consolidation is proposed, where every eight existing shares of HKD 0.01 each will be consolidated into one share of HKD 0.08 [1] - The consolidation will also require shareholder approval and will take effect on the second business day following the special general meeting [1] - Post-consolidation, the trading unit on the Stock Exchange will change from 4,000 existing shares to 10,000 consolidated shares [1] Group 3: Rights Issue - Following the increase in authorized share capital and share consolidation, the board suggests a rights issue where every two consolidated shares will entitle shareholders to one new share at a subscription price of HKD 0.28 [2] - The rights issue aims to issue up to 77,833,203 shares, potentially raising approximately HKD 21.8 million before expenses [2] - The shares to be issued represent about 50% of the total consolidated shares post-consolidation and about 33.3% of the enlarged issued consolidated shares [2] Group 4: Use of Proceeds - The net proceeds from the rights issue are expected to be approximately HKD 9.4 million after expenses [2] - The company plans to allocate around HKD 8.5 million (90% of the net proceeds) to repay bank borrowings and the remaining HKD 0.9 million (10% of the net proceeds) for general working capital, including employee costs [2]

Group 1 - The company proposes to increase its authorized share capital from HKD 50 million (split into 1 billion shares) to HKD 100 million (split into 2 billion shares) by adding an additional 1 billion unissued shares, subject to approval at a special general meeting [1] - Following the increase in authorized share capital, the company plans to conduct a rights issue at a subscription price of HKD 0.08 per share, offering 1 share for every share held as of the record date, aiming to issue between 560 million and 641 million shares to raise at least approximately HKD 44.82 million before expenses [1] Group 2 - The estimated net proceeds from the rights issue will be at least approximately HKD 40.82 million and not exceeding approximately HKD 47.28 million, depending on the exercise of outstanding share options [2] - The company intends to use the net proceeds for several purposes, including: (i) developing existing pharmaceutical wholesale and distribution business, as well as dialysis treatment and consulting services, and potential investments in the healthcare sector; (ii) settling trade and other payables of approximately HKD 5 million and repaying a director's loan and accrued interest of approximately HKD 8.5 million; (iii) general working capital, including salaries, rent, professional fees, and other corporate expenses [2]

Group 1 - The company proposes to increase its authorized share capital from HKD 50 million (split into 1 billion shares) to HKD 100 million (split into 2 billion shares) by issuing an additional 1 billion unissued shares, subject to approval at a special shareholders' meeting [1] - Following the increase in authorized share capital, the company plans to conduct a rights issue at a subscription price of HKD 0.08 per share, offering 560 million to 641 million shares to raise at least approximately HKD 44.82 million before expenses [1] - The estimated net proceeds from the rights issue will be at least approximately HKD 40.82 million, assuming no changes in the number of shares issued prior to the record date [2] Group 2 - The company intends to use the net proceeds from the rights issue for several purposes, including the development of existing pharmaceutical wholesale and distribution businesses, as well as dialysis treatment and consulting services [2] - Part of the proceeds will be allocated to settle trade and other payables of approximately HKD 5 million and to repay a director's loan and accrued interest of approximately HKD 8.5 million [2] - The remaining funds will be utilized for general working capital, which includes but is not limited to salaries, rent expenses, professional fees, and other corporate expenses [2]

Group 1 - The company announced a rights issue where every two existing shares entitle shareholders to three new shares, with a total of 114,759,630 shares subscribed, representing approximately 43.7% of the total offered shares [1] - The rights issue was not fully subscribed, leaving a shortfall of 147,913,026 shares, which accounts for about 56.3% of the total offered shares, and these shares were successfully placed at a price of HKD 0.13 per share [1] - The total amount raised from the rights issue, including the placement, is approximately HKD 34.1 million, with a net amount of about HKD 32 million after expenses [2] Group 2 - Approximately 95.31% or about HKD 30.5 million (equivalent to around RMB 28 million) of the net proceeds will be used to acquire properties, factories, and machinery for production lines in China by the first half of 2027 [2] - The remaining net proceeds of about 4.69% or approximately HKD 1.5 million will be allocated for general working capital of the group by the second half of 2026 [2]